Join the conversation

Key facts

Norgine fact sheet

We are a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net product sales were EUR 345 million, up 17 per cent.

We employ over 1,000 people across our commercial, development and manufacturing operations. We manage all aspects of product development, production, marketing, sales and supply.

Our approach and infrastructure is integrated and focused on ensuring that we win and deliver upon partnership opportunities for growth.

Our employees

We employ over 1,000 employees. We have demonstrated manufacturing, clinical development, medical, pharmacovigilance, regulatory, market access, sales and marketing expertise across Europe, Australia and New Zealand.

2017 performance

Total net product sales

Continues long track record of growth, up 17 per cent.

Key partnering milestones

Partnering is core to our business. Our approach to partnering is flexible which helps to meet the challenges faced by the pharmaceutical sector. We find and work with partners with complementary skills and a shared vision for improving healthcare and the lives of patients and their carers.

NORGINE B.V. TO DIVEST ITS CANADIAN ASSETS ACQUIRED THROUGH MERUS LABS INTERNATIONAL INC. TO SEARCHLIGHT PHARMA

October 2018

Norgine B.V. and Shield Therapeutics enter into an exclusive licence agreement for the commercialisation of Feraccru® in Europe, Australia and New Zealand

September 2018

NEW AND EXCLUSIVE DISTRIBUTION AGREEMENT FOR ENDOCUFF VISIONTM IN EUROPE, MIDDLE EAST AND AFRICA

September 2018

Norgine receives US FDA approval for PLENVU® (NER1006). PLENVU® will be available in the US through Salix in the second half of 2018.

May 2018

Norgine granted rights to AMICUS to commercialise MOVIPREP® in Macedonia and Serbia

November 2017

Norgine expands its partnership with A Pharm s.r.l. to commercialise ZIVEREL® PLUS

November 2017

Norgine B.V. acquires Merus Labs International Inc.

July 2017

Norgine entered into an agreement with Noventure S.L., under which Norgine will distribute GELSECTAN® in Spain, Portugal and Andorra

March 2017

Norgine enters co-promotion agreement with Pfizer in Germany for INFLECTRA® (infliximab) for the treatment of Crohn’s disease and ulcerative colitis

September 2016

Norgine licensed out NER1006 (PLENVU) to Valeant Pharmaceuticals for US and Canada

We use strictly necessary, performance and functionality cookies to give you the best experience while using this website. We do not employ any marketing cookies on this website. Only continue if you accept. AcceptRead more